The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer
Abstract
BACKGROUND.: The presence of multiple determinants of aggressive cancer biology may impact prostate cancer‐specific mortality (PCSM) rates compared with fewer factors. The authors estimated PCSM after radiation therapy with short‐course androgen suppression therapy (RT+AST) or radical prostatectomy (RP) in men with clinically localized, intermediate‐risk to high‐risk prostate cancer. METHODS.: The study cohort included 3240 men treated from 1981 to 2002 with RT with 6 months of AST (n = 550) or RP (n = 2690) for localized prostate cancer with at least 1 risk factor (prostate‐specific antigen [PSA] >10 ng/mL, biopsy Gleason score 7–10, or clinical tumor category T2b or T2c). Competing risks regression analyses were used to determine whether the number of risk factors present was associated with time to PCSM. RESULTS.: Men with all 3 risk factors had significantly shorter time to PCSM after RT+AST (adjusted hazards ratio [HR] of 9.3; 95% confidence interval [95% CI], 1.9–44.5 [PGray = .005]) or RP (adjusted HR of 6.3; 95% CI, 3.2–12.2 [PGray < .001]) when compared with men with any 1 or 2 risk factors. The 7‐year estimates of PCSM for men having 1, 2, or 3 risk factors were 0.83% (95% CI, 0.27–1.4%), 2.6% (95% CI, 1.0–4.2%), and 12.6% (95% CI, 7.1–18.1%), respectively. CONCLUSIONS.: Men with multiple determinants of intermediate‐risk to high‐risk prostate cancer have significantly increased estimates of PCSM despite aggressive therapy compared with men with only 1 or 2 determinants. These men are appropriate candidates for enrollment onto randomized controlled trials evaluating the benefit of adding systemic therapies such as docetaxel to RT+AST or RP. Cancer 2006. © 2006 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Zietman, A. L., DeSilvio, M. L., Slater, J. D., Rossi, C. J., Miller, D. W., Adams, J. A., & Shipley, W. U. (2005) · JAMA · doi:10.1001/jama.294.10.1233 · Cited by 1,224
Cited by
Cooperberg, M. R., Hilton, J. F., & Carroll, P. R. (2011) · Cancer · doi:10.1002/cncr.26169 · Cited by 457
Self-citationActive surveillance for the management of prostate cancer in a contemporary cohort
Dall'Era, M. A., Konety, B. R., Cowan, J. E., Shinohara, K., Stauf, F., Cooperberg, M. R., Meng, M. V., Kane, C. J., Perez, N., Master, V. A., et al. (2008) · Cancer · doi:10.1002/cncr.23502 · Cited by 404
Self-citationAmerican Cancer Society prostate cancer survivorship care guidelines
Skolarus, T. A., Wolf, A. M. D., Erb, N. L., Brooks, D. D., Rivers, B. M., Underwood, W., Salner, A. L., Zelefsky, M. J., Aragon‐Ching, J. B., Slovin, S. F., et al. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21234 · Cited by 398
Antonarakis, E. S., Feng, Z., Trock, B. J., Humphreys, E. B., Carducci, M. A., Partin, A. W., Walsh, P. C., & Eisenberger, M. A. (2012) · BJU International · doi:10.1111/j.1464-410x.2011.10422.x · Cited by 276
Active surveillance for early‐stage prostate cancer: Review of the current literature
Dall'Era, M. A., Cooperberg, M. R., Chan, J. M., Davies, B. J., Albertsen, P. C., Klotz, L. H., Warlick, C. A., Holmberg, L., Bailey, D. E., Wallace, M. E., et al. (2008) · Cancer · doi:10.1002/cncr.23373 · Cited by 273
Self-citation
Metadata
- Authors
- Tsai, H. K., Chen, M., McLeod, D. G., Carroll, P. R., Richie, J. P., & D'Amico, A. V.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2006-10-12
- Volume
- 107
- Issue
- 11
- Pages
- 2597-2603
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2002681681
- Cited by
- 166
- References
- 3
- FWCI
- 18.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer. https://app.cochat.ai/papers/10.1002/cncr.22279
- The paper
- Tsai, H. K., Chen, M., McLeod, D. G., Carroll, P. R., Richie, J. P., & D'Amico, A. V. (2006). Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer. Cancer. https://doi.org/10.1002/cncr.22279
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.